Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement
Executive Summary
Second pharma charity kickback settlement in six months resolves claims Pfizer used charity to pay Medicare patient copays for three drugs.
You may also be interested in...
US FDA Loses Orphan Exclusivity Case While HHS Wins Dismissal Of Pfizer Kickback Complaint
In rare loss for FDA, appeals court reverses district court decision tossing Catalyst’s suit over Orphan Drug Act, saying deference should not have been granted to agency’s interpretation. District court finds it is too early to rule on one Pfizer charity co-pay program but backs broad reading of Anti-Kickback Statute.
Pfizer Switches To Offense In Charity Co-Payment Suit Against HHS
Pfizer is one of 10 pharma companies that have reached settlements with the US Department of Justice over their relationships with co-pay assistance foundations. It now seeks a declaratory judgement that proposed programs for its heart drug tafamidis do not violate the anti-kickback statute.
Patient Assistance Charity Programs Restricted Under Jazz, Lundbeck Settlements
Jazz, Lundbeck and Alexion settle DoJ allegations they paid kickbacks through co-pay assistance foundations, but only two of them enter corporate integrity agreements.